Copper in Colorectal Cancer: From Copper-related Mechanisms to Clinical Cancer Therapies

Overview

Journal Clin Transl Med

Publisher Wiley

Specialty General Medicine

Date 2024 May 28

PMID 38804588

Authors

Yuhong Wang

Pei Pei

Kai Yang

Lingchuan Guo

Yuan Li

Affiliations

Soon will be listed here.

Abstract

Copper, a trace element and vital cofactor, plays a crucial role in the maintenance of biological functions. Recent evidence has established significant correlations between copper levels, cancer development and metastasis. The strong redox-active properties of copper offer both benefits and disadvantages to cancer cells. The intestinal tract, which is primarily responsible for copper uptake and regulation, may suffer from an imbalance in copper homeostasis. Colorectal cancer (CRC) is the most prevalent primary cancer of the intestinal tract and is an aggressive malignant disease with limited therapeutic options. Current research is primarily focused on the relationship between copper and CRC. Innovative concepts, such as cuproplasia and cuproptosis, are being explored to understand copper-related cellular proliferation and death. Cuproplasia is the regulation of cell proliferation that is mediated by both enzymatic and nonenzymatic copper-modulated activities. Whereas, cuproptosis refers to cell death induced by excess copper via promoting the abnormal oligomerisation of lipoylated proteins within the tricarboxylic acid cycle, as well as by diminishing the levels of iron-sulphur cluster proteins. A comprehensive understanding of copper-related cellular proliferation and death mechanisms offers new avenues for CRC treatment. In this review, we summarise the evolving molecular mechanisms, ranging from abnormal intracellular copper concentrations to the copper-related proteins that are being discovered, and discuss the role of copper in the pathogenesis, progression and potential therapies for CRC. Understanding the relationship between copper and CRC will help provide a comprehensive theoretical foundation for innovative treatment strategies in CRC management.

Citing Articles

Single-cell and Multi-omics Analysis Confirmed the Signature and Potential Targets of Cuproptosis in Colorectal Cancer.

Jiang T, Wang Z, Sun Z, Lv H, Li G, Li H J Cancer. 2025; 16(4):1264-1280.

PMID: 39895793 PMC: 11786029. DOI: 10.7150/jca.104702.

Prognostic models of immune-related cell death and stress unveil mechanisms driving macrophage phenotypic evolution in colorectal cancer.

Liu H, Zhang C, Peng S, Yin Y, Xu Y, Wu S J Transl Med. 2025; 23(1):127.

PMID: 39875913 PMC: 11776142. DOI: 10.1186/s12967-025-06143-9.

Copper in colorectal cancer patients: a systematic review and meta-analysis.

Munoz-Bravo C, Marin-Burdallo I, Gonzalez-Herrera L, Gonzalez-Palacios Torres C, Lozano-Lorca M, Jimenez-Moleon J Carcinogenesis. 2025; 46(1).

PMID: 39847508 PMC: 11826919. DOI: 10.1093/carcin/bgaf001.

Copper-instigated modulatory cell mortality mechanisms and progress in kidney diseases.

Ren X, Zhao L, Hao Y, Huang X, Lv G, Zhou X Ren Fail. 2025; 47(1):2431142.

PMID: 39805816 PMC: 11734396. DOI: 10.1080/0886022X.2024.2431142.

Targeting CDK1 and copper homeostasis in breast cancer via a nanopolymer drug delivery system.

Shang N, Zhu L, Li Y, Song C, Liu X Cell Biol Toxicol. 2024; 41(1):16.

PMID: 39724454 PMC: 11671568. DOI: 10.1007/s10565-024-09958-2.

References

Li Y, Chen F, Chen J, Chan S, He Y, Liu W . Disulfiram/Copper Induces Antitumor Activity against Both Nasopharyngeal Cancer Cells and Cancer-Associated Fibroblasts through ROS/MAPK and Ferroptosis Pathways. Cancers (Basel). 2020; 12(1). PMC: 7017005. DOI: 10.3390/cancers12010138. View

BREMNER I . Manifestations of copper excess. Am J Clin Nutr. 1998; 67(5 Suppl):1069S-1073S. DOI: 10.1093/ajcn/67.5.1069S. View

Shanbhag V, Gudekar N, Jasmer K, Papageorgiou C, Singh K, Petris M . Copper metabolism as a unique vulnerability in cancer. Biochim Biophys Acta Mol Cell Res. 2020; 1868(2):118893. PMC: 7779655. DOI: 10.1016/j.bbamcr.2020.118893. View

Lonnerdal B . Intestinal regulation of copper homeostasis: a developmental perspective. Am J Clin Nutr. 2008; 88(3):846S-50S. DOI: 10.1093/ajcn/88.3.846S. View

Blanusa M, Varnai V, Piasek M, Kostial K . Chelators as antidotes of metal toxicity: therapeutic and experimental aspects. Curr Med Chem. 2005; 12(23):2771-94. DOI: 10.2174/092986705774462987. View

Zhang X, Walke G, Horvath I, Kumar R, Blockhuys S, Holgersson S . Memo1 binds reduced copper ions, interacts with copper chaperone Atox1, and protects against copper-mediated redox activity in vitro. Proc Natl Acad Sci U S A. 2022; 119(37):e2206905119. PMC: 9477392. DOI: 10.1073/pnas.2206905119. View

OBrien H, Davoodian T, Johnson M . The promise of copper ionophores as antimicrobials. Curr Opin Microbiol. 2023; 75:102355. PMC: 10529258. DOI: 10.1016/j.mib.2023.102355. View

Zhang B, Li Y, Song L, Xi H, Wang S, Yu C . Cuproplasia characterization in colon cancer assists to predict prognosis and immunotherapeutic response. Front Oncol. 2023; 13:1061084. PMC: 10060792. DOI: 10.3389/fonc.2023.1061084. View

Dam J, Ismail Z, Kurebwa T, Gangat N, Harmse L, Marques H . Synthesis of copper and zinc 2-(pyridin-2-yl)imidazo[1,2-a]pyridine complexes and their potential anticancer activity. Eur J Med Chem. 2016; 126:353-368. DOI: 10.1016/j.ejmech.2016.10.041. View

10.

Gu M, Cooper J, Butler P, Walker A, Mistry P, Dooley J . Oxidative-phosphorylation defects in liver of patients with Wilson's disease. Lancet. 2000; 356(9228):469-74. DOI: 10.1016/s0140-6736(00)02556-3. View

11.

Zhang P, Zhou C, Ren X, Jing Q, Gao Y, Yang C . Inhibiting the compensatory elevation of xCT collaborates with disulfiram/copper-induced GSH consumption for cascade ferroptosis and cuproptosis. Redox Biol. 2023; 69:103007. PMC: 10788306. DOI: 10.1016/j.redox.2023.103007. View

12.

Itoh S, Kim H, Nakagawa O, Ozumi K, Lessner S, Aoki H . Novel role of antioxidant-1 (Atox1) as a copper-dependent transcription factor involved in cell proliferation. J Biol Chem. 2008; 283(14):9157-67. PMC: 2431038. DOI: 10.1074/jbc.M709463200. View

13.

Liang Z, Tsai W, Lee M, Savaraj N, Kuo M . Specificity protein 1 (sp1) oscillation is involved in copper homeostasis maintenance by regulating human high-affinity copper transporter 1 expression. Mol Pharmacol. 2011; 81(3):455-64. PMC: 3286298. DOI: 10.1124/mol.111.076422. View

14.

Gupta S, Shukla V, VAIDYA M, Roy S, Gupta S . Serum and tissue trace elements in colorectal cancer. J Surg Oncol. 1993; 52(3):172-5. DOI: 10.1002/jso.2930520311. View

15.

Ashkenazi A, Levin S, Djaldetti M, FISHEL E, Benvenisti D . The syndrome of neonatal copper deficiency. Pediatrics. 1973; 52(4):525-33. View

16.

Gundelach J, Madhavan A, Wettstein P, Bram R . The anticancer drug Dp44mT inhibits T-cell activation and CD25 through a copper-dependent mechanism. FASEB J. 2012; 27(2):782-92. DOI: 10.1096/fj.12-215756. View

17.

Wang Y, Pei P, Yang K, Guo L, Li Y . Copper in colorectal cancer: From copper-related mechanisms to clinical cancer therapies. Clin Transl Med. 2024; 14(6):e1724. PMC: 11131360. DOI: 10.1002/ctm2.1724. View

18.

Lowndes S, Harris A . The role of copper in tumour angiogenesis. J Mammary Gland Biol Neoplasia. 2006; 10(4):299-310. DOI: 10.1007/s10911-006-9003-7. View

19.

Wang W, Lu K, Jiang X, Wei Q, Zhu L, Wang X . Ferroptosis inducers enhanced cuproptosis induced by copper ionophores in primary liver cancer. J Exp Clin Cancer Res. 2023; 42(1):142. PMC: 10242978. DOI: 10.1186/s13046-023-02720-2. View

20.

Sharp P . Ctr1 and its role in body copper homeostasis. Int J Biochem Cell Biol. 2003; 35(3):288-91. DOI: 10.1016/s1357-2725(02)00134-6. View